Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBT (2016 - 2025)

Historic EBT for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$67.1 million.

  • Ascendis Pharma A's EBT rose 3779.41% to -$67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$245.1 million, marking a year-over-year increase of 4581.03%. This contributed to the annual value of -$404.0 million for FY2024, which is 2081.3% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's EBT is -$67.1 million, which was up 3779.41% from -$39.6 million recorded in Q2 2025.
  • Ascendis Pharma A's EBT's 5-year high stood at -$39.6 million during Q2 2025, with a 5-year trough of -$206.2 million in Q4 2022.
  • Over the past 5 years, Ascendis Pharma A's median EBT value was -$117.5 million (recorded in 2024), while the average stood at -$114.8 million.
  • In the last 5 years, Ascendis Pharma A's EBT crashed by 8504.18% in 2022 and then surged by 6628.78% in 2025.
  • Ascendis Pharma A's EBT (Quarter) stood at -$121.5 million in 2021, then crashed by 69.73% to -$206.2 million in 2022, then surged by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then tumbled by 67.89% to -$67.1 million in 2025.
  • Its EBT stands at -$67.1 million for Q3 2025, versus -$39.6 million for Q2 2025 and -$98.4 million for Q1 2025.